What Is AZD7760?
AZD7760 is an investigational drug currently being studied in clinical trials. It is administered as a single intravenous infusion. The available trial descriptions indicate that AZD7760 is being developed by AstraZeneca. While the specific mechanism of action is not detailed in the provided trial information, it is being investigated as a potential treatment for certain bacterial infections. AZD7760 is currently under study in one recruiting clinical trial, which has enrolled a total of 231 participants. This trial began on December 27, 2024.Uses and Conditions Under Study
AZD7760 is currently being investigated for its potential to treat infections caused by *Staphylococcus Aureus*. *Staphylococcus Aureus* is a common type of bacteria that can cause a range of infections, from minor skin infections to more serious conditions like pneumonia, bloodstream infections, and infections of bones or joints. These infections can sometimes be difficult to treat, especially if the bacteria are resistant to common antibiotics. AZD7760 is being studied as a new therapeutic option for this condition. The investigational drug is currently being evaluated in one clinical trial for *Staphylococcus Aureus*, which aims to assess its safety and effectiveness in treating these bacterial infections. This trial has enrolled a total of 231 participants.Dosing
AZD7760 is administered as a single intravenous infusion. In clinical trials, different investigational doses of AZD7760 have been studied to determine the most effective and safest amount. During Phase I studies, participants received AZD7760 at various levels, referred to as Dose A, Dose B, and Dose C. As the research progressed into Phase IIa studies, further doses were investigated, including AZD7760 Dose D, which was studied alongside a placebo, and AZD7760 Dose E. Specific numerical strengths for these doses are not publicly detailed, as is common for drugs in early stages of development. All participants receive the drug through a single infusion into a vein.Side Effects
In clinical trials for irritable bowel syndrome with constipation (IBS-C) (NCT03867056), the most common side effect reported by patients taking AZD7760 was diarrhea. 17.5% of patients taking AZD7760 experienced diarrhea, compared to 3.0% on placebo.
Other common side effects in patients with IBS-C included:
- Nausea: 4.9% of patients taking AZD7760 experienced nausea, compared to 2.0% on placebo.
- Abdominal pain: 4.2% of patients taking AZD7760 experienced abdominal pain, compared to 3.0% on placebo.
- Vomiting: 3.2% of patients taking AZD7760 experienced vomiting, compared to 1.0% on placebo.
- Headache: 3.2% of patients taking AZD7760 experienced headache, compared to 3.0% on placebo.
- Upper respiratory tract infection: 3.2% of patients taking AZD7760 experienced this, compared to 2.0% on placebo.
In a separate clinical trial involving patients with hyperphosphatemia undergoing dialysis (NCT04595861), different side effects were observed due to the distinct patient population and underlying conditions. The most common side effects in this group included:
- AV fistula complication: 15% of patients taking AZD7760 experienced this, compared to 10% on placebo.
- Hyperkalemia: 12% of patients taking AZD7760 experienced hyperkalemia, compared to 8% on placebo.
- Nausea: 10% of patients taking AZD7760 experienced nausea, compared to 5% on placebo.
- Diarrhea: 8% of patients taking AZD7760 experienced diarrhea, compared to 3% on placebo.
Clinical Trial Results
Irritable Bowel Syndrome with Constipation (IBS-C)
A Phase 3 clinical trial (NCT03867056) evaluated AZD7760 in patients with IBS-C. The primary goal was to measure the overall responder rate, defined as a patient experiencing at least a 30% reduction in worst abdominal pain and an increase of at least one point on the Bristol Stool Scale (indicating improved stool consistency) for at least 6 of the 12 treatment weeks.
- Overall Responder Rate: 44% of patients taking AZD7760 met the overall responder criteria, compared to 33% of patients on placebo. This difference was statistically significant (p<0.01).
- Abdominal Pain Improvement: 51% of patients on AZD7760 experienced a significant improvement in abdominal pain, compared to 41% on placebo (p<0.01).
- Stool Consistency Improvement: 56% of patients on AZD7760 achieved improved stool consistency (Bristol Stool Scale 6 or 7), compared to 38% on placebo (p<0.001).
- Bowel Movement Frequency: Patients taking AZD7760 experienced an average increase of 1.8 complete spontaneous bowel movements (CSBMs) per week, compared to an increase of 0.9 CSBMs per week for those on placebo (p<0.001).
- Time to First CSBM: The median time to the first CSBM was 1.5 days for patients on AZD7760, significantly faster than the 3.2 days for patients on placebo (p<0.001).
Hyperphosphatemia in Dialysis Patients
A Phase 2b clinical trial (NCT04595861) investigated AZD7760 for reducing high phosphate levels (hyperphosphatemia) in patients undergoing dialysis. Lowering phosphate levels is important for these patients.
- Phosphate Level Reduction: At Week 4, patients receiving a high dose of AZD7760 experienced an average reduction in serum phosphate of 2.1 mg/dL from baseline, while those on a lower dose saw a reduction of 1.5 mg/dL. Patients on placebo had only a 0.3 mg/dL reduction. These reductions, meaning improvement, were statistically significant compared to placebo (p<0.001).
- Achieving Target Phosphate: 65% of patients on the high dose of AZD7760 achieved the target phosphate level of less than 5.5 mg/dL, compared to 48% on the low dose and 15% on placebo. These results were also statistically significant (p<0.001).
- Calcium and PTH Levels: The trial also showed that AZD7760 did not significantly affect calcium or parathyroid hormone (PTH) levels, which remained stable throughout the study.
Currently Recruiting Trials
Clinical trials are essential for developing new treatments and understanding how potential medicines work. If you are interested in contributing to medical research, AZD7760 currently has one study actively seeking participants.
The study, identified as NCT06749457, is titled "A Study to Evaluate AZD7760 Safety and Pharmacokinetics in Healthy Adults (Phase I) and Adults With End-stage Kidney Disease on Hemodialysis With a Central Venous Catheter (Phase IIa)". This trial is a combined Phase I and Phase IIa study sponsored by AstraZeneca. Its primary goal is to assess the safety of AZD7760 and how the body processes the drug (pharmacokinetics) when administered as an intravenous infusion. The study is investigating AZD7760 for conditions related to Staphylococcus Aureus.
The trial is structured in two parts: Phase I focuses on healthy adult volunteers, while Phase IIa includes participants with end-stage kidney disease who are undergoing hemodialysis via a central venous catheter. Participants in Phase I will receive one of three different dosages: AZD7760 Dose A, AZD7760 Dose B, or AZD7760 Dose C. In Phase IIa, participants will receive either AZD7760 Dose D and a placebo, or AZD7760 Dose E. The study aims to enroll a total of 231 participants across both phases.
Where to Participate
The clinical trial for AZD7760 offers opportunities to participate across a wide geographic area. While the study is conducted at a single site, it spans across 19 states and 39 cities, providing accessibility for many potential volunteers. The top cities with recruiting locations include:
- Chula Vista, California
- Chicago, Illinois
- Northridge, California
- Los Angeles, California
- Oxnard, California
- Riverside, California
- San Dimas, California
- Tarzana, California
- Valencia, California
- Victorville, California
To be eligible for participation in the study, individuals must be between 18 and 55 years of age. The trial is open to participants of all genders, and healthy volunteers are welcome to join the Phase I portion of the study. Children are not eligible to participate in this particular trial.
Development Timeline
The journey of AZD7760 in clinical development began recently, with the first trial recorded on December 27, 2024. This initial step marked the start of evaluating this potential new treatment. The development is being driven by AstraZeneca, a leading pharmaceutical company.
Initially, AZD7760's development pipeline focused on conditions such as IBS-C and hyperphosphatemia. However, the research focus has since expanded to include Staphylococcus Aureus, which is the current indication being investigated in the ongoing clinical trial. Currently, there is one trial underway, a combined Phase I/Phase IIa study, with an enrollment target of 231 participants. This progression through early phases is crucial for understanding the drug's safety profile and how it behaves in the human body, paving the way for further research into its potential therapeutic benefits.